CYTH — Cyclo Therapeutics Share News
0.000.00%
Last trade - 00:00- $23.04m
- $34.29m
- $1.08m
Cyclo Therapeutics: Jumps after genetic disorder treatment meets trial goal
Brief: Cyclo Therapeutics Files For Mixed Shelf Of Up To $100 Mln
Brief: Cyclo Therapeutics Reports Q4 And FY20 Financial Results
Cyclo: Surges on EMA boost for genetic disorder drug development
Brief: Cyclo Therapeutics Receives Positive Opinion From European Medicines Agency On The Agreement Of A Paediatric Investigation Plan For Trappsol Cyclo
Brief: Cyclo Therapeutics Announces Last Patient Last Visit In Phase 1/2 Trial Evaluating Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C
U.S. RESEARCH ROUNDUP- Akamai Technologies, Super League Gaming, Twitter
Cyclo Therapeutics: Rises on positive data on its genetic disorder drug
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:47 AM
Brief: Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Lead Candidate, Trappsol Cyclo, At WORLDSymposium 2021
U.S. STOCKS ON THE MOVE-Cyclo Therapeutics, Atomera Inc, Conagra Brands Inc
Cyclo Therapeutics: Rises on positive data from genetic disorder treatment trial
Brief: Cyclo Therapeutics Announces Positive Efficacy Data From Extension Protocol With Trappsol Cyclo In Patients With Niemann-Pick Disease Type C
Brief: Cyclo Therapeutics Reports On 18 Month Expanded Access Program In Single Alzheimer's Patient
Brief: Cyclo Therapeutics Reports Positive Feedback From EMA On Trial Design For Niemann-Pick Disease Type C
Brief: Cyclo Therapeutics Closes $2.0 Mln Private Placement
Brief: Cyclo Therapeutics Announces Completion Of Enrollment In Its Extension Protocol To The Phase I Trial To Evaluate Trappsol Cyclo
Brief: Cyclo Therapeutics Signs Agreement With Worldwide Clinical Trials To Conduct Pivotal Trial In Niemann-Pick Disease Type C
Brief: Cyclo Therapeutics Signs Agreement With Worldwide Clinical Trials To Conduct Alzheimer’S Disease Clinical Trial